CN105168723B - A topical Chinese medicinal composition for treating cancer pain, and its preparation method - Google Patents
A topical Chinese medicinal composition for treating cancer pain, and its preparation method Download PDFInfo
- Publication number
- CN105168723B CN105168723B CN201510675585.1A CN201510675585A CN105168723B CN 105168723 B CN105168723 B CN 105168723B CN 201510675585 A CN201510675585 A CN 201510675585A CN 105168723 B CN105168723 B CN 105168723B
- Authority
- CN
- China
- Prior art keywords
- parts
- pain
- traditional chinese
- chinese medicine
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an external traditional Chinese medicine composition for treating cancer pain, which is prepared by the following steps: taking 25-35 parts of dragon's blood, 4-6 parts of toad venom, 60-90 parts of raw arisaema tuber, 60-90 parts of monkshood, 25-35 parts of natural indigo, 25-35 parts of borneol, 50-70 parts of frankincense and 50-70 parts of myrrh, grinding into fine powder, sieving with a 200-mesh sieve, adding proper auxiliary materials, and preparing into external ointment or patch. The topical Chinese medicinal composition can effectively relieve or eliminate cancer pain.
Description
Technical Field
The invention relates to an external traditional Chinese medicine composition for treating cancer pain and a preparation method of the composition, and belongs to the field of traditional Chinese medicines.
Background
Chronic cancer pain is chronic pain caused by malignant tumor, and the pain incidence rate is highest in subjective symptoms of cancer patients. The symptoms of 25-40% of the patients with malignant tumors in initial diagnosis, 30-50% of the patients with cancer in the active treatment period and 70-90% of the patients with cancer in the advanced cancer period can appear, and many cancer patients have to suffer from the great pain of cancer pain in the last period of life. According to survey, 61.6-69% of patients in China are accompanied by cancer pain, 69% of patients in hospitalization are accompanied by pain, wherein the mild pain accounts for 21.5%, the moderate pain accounts for 19%, and the severe pain accounts for 28.5%.
Drug therapy is the primary method of cancer pain treatment. At present, the clinical application of the treatment method of 'three-step analgesics' recommended by WHO is mainly, and the treatment principle can be roughly summarized into five points, namely: orally administered, on time, in steps, individually administered, and paying attention to specific details. For patients with first-degree (mild) pain, antipyretic analgesics such as aspirin are mainly selected; for secondary (moderate) pain, weak opioids, such as codeine; strong opioid, such as morphine, is preferred for tertiary (severe) pain. For most patients, the treatment can relieve cancer pain. However, the drugs used for a long time have great toxic and side effects, are most commonly constipation, sedation, nausea, vomiting, respiratory depression and the like, have strong dependence and addiction, and often seriously affect the life quality of patients. Therefore, it is highly desirable to reduce unnecessary side effects while providing adequate analgesia.
Disclosure of Invention
The invention aims to provide a novel external traditional Chinese medicine composition which can effectively treat cancer pain. Also provides a preparation method of the composition.
The purpose of the invention is realized by the following technical scheme.
Scheme 1: an external traditional Chinese medicine composition for cancer pain comprises the following active ingredients in parts by weight: 25-35 parts of dragon's blood, 4-6 parts of toad venom, 60-90 parts of raw arisaema tuber, 60-90 parts of common monkshood mother root, 25-35 parts of natural indigo, 25-35 parts of borneol, 50-70 parts of frankincense and 50-70 parts of myrrh.
Preferably, the raw material medicines comprise: 30 parts of dragon's blood, 5 parts of toad venom, 75 parts of raw arisaema tuber, 75 parts of common monkshood mother root, 30 parts of natural indigo, 30 parts of borneol, 60 parts of frankincense and 60 parts of myrrh.
Scheme 2: on the basis of the raw material medicines in the scheme 1, 2.5-3.5 parts of rhododendron molle, 25-35 parts of erycibe obtusifolia and 40-60 parts of cassia twig are added. Preferably, the three raw material medicines comprise: 3 parts of rhododendron molle, 30 parts of Erycibe obtusifolia and 50 parts of cassia twig.
The prescription of the invention comprises: the monarch drug dragon's blood is sweet and salty in taste, flat and slightly toxic, and has the effects of promoting blood circulation, removing blood stasis, relieving pain, stopping bleeding, promoting granulation and healing sore after being taken orally; the ministerial drug indigo naturalis cools blood, detoxifies and clears heat, and has moderate-intensity inhibiting effect on animal transplantation tumor; the toad is pungent, cool and slightly toxic in flavor, and has the effects of detoxifying, relieving pain and refreshing mind; radix Aconiti is bitter and hot, has strong toxicity and accumulation, and has effects of dispelling pathogenic wind, removing dampness, warming channels and relieving pain; the raw arisaema with bitter, pungent and warm taste has the functions of eliminating dampness and phlegm, dispelling wind and relieving spasm, and externally used for eliminating stagnation and reducing swelling, and is used as a ministerial drug; borneol, an adjuvant drug, is pungent, bitter and slightly cool in taste, has the effects of inducing resuscitation and refreshing mind, promoting blood circulation and dredging channels, and relieving swelling and pain, has an analgesic effect when being locally applied, and has the function of promoting the transdermal absorption of the drug as the component of elemi ; the frankincense and the myrrh are mutually reinforced, the frankincense is bitter and pungent in taste, warm, nontoxic, and capable of promoting blood circulation to relieve pain and stretching tendons; the medicine is bitter and pungent, warm and nontoxic. The traditional Chinese medicine composition has the effects of detoxifying, resolving masses, relieving swelling and pain, and is mainly used for treating pain caused by various cancers and swellings, which is caused by qi stagnation and blood stasis, pain and swelling, and the pain is slow, rapid, accompanied with fullness and distention in chest and abdomen, and eructation; or pain with stabbing pain, fixed pain, pain with pressure, severe pain at night, dark and gloomy complexion, purple tongue with ecchymosis, and astringent and sluggish pulse.
When in use, the raw materials are ground into fine powder and sieved by a 200-mesh sieve to obtain fine powder. Cleaning pain part before application, concocting the medicinal powder with boiling water into paste, spreading on a plaster cotton pad with thickness of about 0.3cm and area diameter of about 2cm larger than that of pain part skin, sequentially covering a layer of gauze and a layer of plastic film on the ointment, and sealing and fixing with desensitizing adhesive tape. The medicine is applied for 1 time every day for 8-12 hours.
Advantageous effects
In order to prove the effect of the medicament, the inventor carries out a series of clinical research experiments, and the main contents of the experiments are as follows:
1. clinical data
1.1 sources of cases
And the oncology inpatients of the Guanann door hospital in Chinese medical science institute of Guangan in 2011 and 3 to 2012 meet the diagnosis standard.
1.1.1 diagnostic criteria
(1) The tumor diagnosis standard of the international anti-cancer alliance (UICC) is met, and the inpatients with malignant tumors are diagnosed by pathology and/or cytology or by imaging combined with specific tumor markers.
(2) Patients with pain, and the etiology of pain falls within WHO-defined etiology categories: i.e. pain directly caused by the invasion of tumor development.
(3) According to the seventh edition of "diagnostics of traditional Chinese medicine", cancer pain is differentiated and typed according to its clinical manifestations.
1.1.2 inclusion criteria
(1) Cancer pain patients with definite diagnosis; (the Western medicine diagnosis standard refers to oncology, New edition of common malignant tumor diagnosis and treatment Specifications and New Chinese medicine clinical research guide principles);
(2) the age is more than or equal to 18 and less than or equal to 70 years old;
(3) the weight is more than or equal to 45 kg;
(4) the Ka's behavior state score (KPS) is more than 60 points, and the life cycle is predicted to be more than 3 months;
(5) voluntarily receiving the drug trial treatment and signing an informed consent;
(6) agreement not to use other treatments for cancer pain during the clinical trial except for the three-step analgesic treatment;
(7) hospitalized patients;
1.1.3 exclusion criteria
(1) Those who do not meet the selection criteria;
(2) those with respiratory depression, airway obstruction, hypoxia, or hyperthermia;
(3) patients with obvious heart, brain, liver and kidney dysfunction or patients with bleeding and obvious bleeding tendency;
(4) for patients with opioid, antipyretic analgesic, alcohol allergy and allergic constitution;
(5) pregnant women, lactating women, children, and psychosis patients;
(6) those with advanced disease risk or whose life cycle is less than 3 months;
(7) has history of drug abuse;
(8) with mental, conscious disturbance, unable to cooperate with evaluators;
(9) those undergoing radiotherapy and chemotherapy.
2. Treatment regimens
2.1 study grouping
The study was a randomized, double-blind, placebo-controlled parallel trial. A random digital clinical research table is generated by adopting 6 ASE.12 software simulation, medicine blindness compiling and medicine distribution are carried out, and then the blindness base is stored in duplicate in two independent places of a Guangan hospital scientific research department and a clinical trial institution. According to the research scheme, volunteers meeting the requirements are screened and recorded, and are randomly divided into a treatment group (the external traditional Chinese medicine composition of the invention) and a control group (a placebo group) according to the screening sequence by adopting an envelope random method.
2.2 placebo preparation
Selecting folium Isatidis as main material, and adding corresponding flavoring agent/aromatic; considering that the test medicine contains borneol and produces cool feeling on local skin after being externally applied, the mint volatile oil which has no influence on the treatment of cancer pain is added for simulation. Finally, the placebo with the same appearance, color and taste as the therapeutic drug is prepared. The prepared placebo is dried, crushed, sieved by a 200-mesh sieve and subpackaged into 30g of packaging small bags for clinical practice for later use.
2.3 Observation of drugs
2.3.1 preparation of medicine: the medicine composition of the embodiment 1 of the invention is prepared by grinding the raw materials into fine powder, sieving the fine powder by a 200-mesh sieve, and subpackaging the fine powder into packaging small bags of 30g for later use.
2.3.2 technical Specification:
2.3.2.1 preparing: a single pain part which is relatively fixed and is taken by a patient is selected as an application part, and the affected part is cleaned before use.
2.3.2.2 administration of drugs: mixing 30g of the medicinal powder with boiled water to obtain paste, spreading on a plaster cotton pad, wherein the thickness is about 0.3cm, and the area diameter is about 2cm larger than that of the skin of a pain part.
2.3.2.3 fixing: the ointment is sequentially covered with a layer of gauze and a layer of plastic film, and is sealed and fixed by desensitization adhesive plaster.
2.3.2.4 time: the plaster is applied once a day for about 6 hours.
2.4 methods of treatment
2.4.1 basic treatment: the three-step analgesic drug administration recommended by WHO was used.
2.4.1.1 step I (representative of drug): a noise-inducing and methacin-inducing controlled release tablet;
2.4.1.2 grade II ladder (representative of drug): tramadol sustained release tablets;
2.4.1.3 grade III ladder (representative of drug): controlled release tablets for morphine.
2.4.2 treatment groups: the external application formula is applied for 1 time per day, and the treatment course is 14 days.
2.4.3 control group: administering placebo with the same shape, color and excipient for 1 time/day, and the treatment course is 14 d.
3. Test results
3.1 degree of pain relief
Pain relief: 0 degree: no relief (pain not relieved); 1 degree: mild relief (about 1/4 reduction); 2 degree: moderate relief (greater than 1/2 remission); 3 degrees: significant relief (relief of about 3/4 or greater); 4 degrees: complete remission (disappearance); (pain relief rate) effective rate-significant efficiency (partial relief + complete relief) + micro-efficiency (mild relief). Through statistical analysis, the comparison of the pain relief degrees of two groups of patients after treatment is compared to have statistical difference ((P < 0.05), the total pain relief rate of the invention group (30 cases) is 86.7%, and the total pain relief rate of the placebo group (30 cases) is 66.7%, the former is obviously superior to the latter, and the details are shown in the table I:
table one: comparison of pain relief of two groups of patients after treatment
| Group of | Number of examples | 0 degree | 1 degree | 2 degree | 3 degree | 4 degree | Rate of pain relief |
| Group of the invention | 30 | 4(13.3％) | 3(10.0％) | 9(30.0％) | 6(20.0％) | 8(26.7％) | 86.7％ |
| Placebo group | 30 | 10(33.3％) | 10(33.3％) | 4(13.3％) | 4(13.3％) | 2(6.7％) | 66.7％ |
Note: warp X2The test results are as follows: x2＝12.264，P＝0.015＜0.05。
3.2 dose reduction Rate
The drug dose reduction rate: (pre-group dose-dose at end of observation)/pre-group dose x 100%; through statistical analysis, the pain relief degrees of two groups of patients after treatment are compared to have statistical difference (P is less than 0.05), and the drug dose reduction rate of the invention group (30 cases): 8.93 ± 6.72 (%); drug reduction rate in placebo group (30 cases): 13.5. + -. 7.40 (%), the former being clearly superior to the latter, as specified in Table two:
table two: dose reduction ratio (%)
| Group of | Number of examples | Dose reduction rate (%) | Z value | P value |
| Group of the invention | 30 | 8.93±6.72 | ||
| Placebo group | 30 | -13.5±7.40 | -2.761 | 0.006 |
Note: the results of Wilcoxon rank sum test are as follows: z is-2.761, P is 0.006 < 0.05.
3.3 comparison of therapeutic effects on symptoms of TCM
The standard for judging the curative effect of the traditional Chinese medicine symptoms is as follows: the effect is shown: the symptom score after treatment is reduced by more than or equal to 70 percent compared with that before treatment; the method has the following advantages: the symptom score after treatment is reduced by 36 to 69.9 percent compared with that before treatment; and (4) invalidation: the symptom score after treatment is reduced by less than 36 percent compared with that before treatment; through statistical analysis, the improvement of the traditional Chinese medicine symptoms of two groups of patients after treatment is remarkably statistically different (P is less than 0.01), and the sectional type temple-eliminating pain-relieving external prescription group (30 cases) improves the total effective rate: 83.3 percent; placebo group (30 cases) improved total efficacy: 6.6%, the former is obviously superior to the latter, see table three for details:
table three: improvement of Chinese medicine symptoms after treatment
| Symptoms of traditional Chinese medicine | Inventive group (30 cases) | Placebo group (30 cases) |
| Show effect | 3 | 1 |
| Is effective | 22 | 1 |
| Invalidation | 5 | 28 |
| Total effective rate | 83.3％ | 6.6％ |
Note: warp X2The test results are as follows: x2＝39.998，P＜0.0l。
3.4 Karl score comparison
The evaluation method of Ka's score: the improvement is as follows: the improvement after treatment is more than or equal to 10 minutes than before treatment; and (3) stabilizing: no change before and after treatment; and (3) reducing: after treatment, the number of the medicines is reduced by more than 10 minutes compared with that before treatment. After analysis: the group of the invention is obviously higher than the placebo group (P is less than 0.05), and the details are shown in the fourth table:
table four: comparison of Carlsberg scores between two groups of patients at the end of treatment
| Group of | Number of examples | Improvement of | Stabilization | Reduce | X2Value of | P value |
| Group of the invention | 30 | 8(26.7％) | 21(70％) | 1(3.3％) | ||
| Placebo group | 30 | 2(6.7％) | 21(70％) | 7(23.3％) | 7.899 | 0.020 |
Note: warp X2The test results are as follows: x2＝7.899，P＝0.020＜0.O5
3.5 Living function index comparison
According to the research, the life function indexes of the patients before and after treatment are compared, so that through statistical analysis, the life function indexes of the cancer patients of the two groups of patients after treatment are compared to have statistical difference (P is less than 0.05), and the life function indexes of the sectional type tumor-eliminating and pain-relieving external application group (30 cases) are improved by 13 cases (43.3%); the life function index of the placebo group (30 cases) is improved by 6 cases (20.0 percent), the former is obviously superior to the latter, and the detailed description is shown in the fifth table:
table five: after the treatment, the life function indexes of cancer patients in two groups of patients are compared
| Group of | Number of examples | Improvement of | Stabilization | Reduce | Z value | P value |
| Group of the invention | 30 | 13(43.3％) | 13(43.3％) | 4(13.3％) | ||
| Placebo group | 30 | 6(20.0％) | 15(50.0％) | 9(30.0％) | -2.132 | 0.033 |
Note: the results of Wilcoxon rank sum test are as follows: z-2.132, P0.033 < 0.05
And (4) conclusion: in conclusion, the traditional Chinese medicine composition can obviously relieve cancer pain, reduce the clinical dosage of three-step analgesics and improve the life quality of patients.
4. Improvements in or relating to technology
In the early clinical research process, 3 patients have adverse reactions such as skin breakage, allergy, rash and the like, and the adverse reaction rate is 10%. The inventor carries out repeated experiments to solve the problem, adds three medicines of Chinese azalea flower, Erycibe obtusifolia and cassia twig on the basis of the original prescription, respectively serves as ministerial medicines and conductant medicines, strengthens the potency of the medicines and simultaneously coordinates the properties of the medicines, and through 30 cases of clinical verification, the treatment course can be shortened to within 10 days from the original 14 days without adverse reaction to the skin.
4.1 typical cases
Case one: bone metastasis of lung cancer
In Zhao, a woman, 69 years old, 8 months in 2010, was diagnosed with right lung adenocarcinoma in Beijing tumor hospital, chemotherapy was performed later in the hospital, after four weeks, SD was evaluated, and 1 month in 2011 was reexamined to find thoracic vertebrae metastasis, and later, traditional Chinese and western medicine combined treatment was performed in Guangan hospital, back pain was reported, NRS was scored as 6 points, treatment with second-step analgesics was not satisfactory in effect, and after 10 days of treatment with the formula of example 2 of the present invention after hospital admission, pain was significantly reduced, and was scored as 3 points (treatment with the second-step analgesics was still performed), and no adverse reaction was observed.
Case two: bone metastasis from prostate cancer
Diagnosis of prostate cancer in tumor hospital of Chinese medical academy of sciences in 12 months in 2010 from Zhu, Man, 64 years old, following chest pain due to radioactive particle implantation therapy, ECT diagnosis is: the traditional Chinese medicine composition is mainly used for treating multiple rib metastasis, radiotherapy is carried out later, pain is felt after 4 months, hospitalization is carried out later, the pain score is 5 minutes, tramadol is taken by self for treatment, the curative effect is general, the medicine composition is externally applied by using the formula 2 of the invention later, the pain is obviously relieved after 7 days, the score is 2 minutes, and the pain can be relieved by taking indometacin without adverse reaction.
Case three: liver cancer
Song Dynasty, women, age 76, diagnosis of liver cancer in friendship Hospital, month 1 in 2011, intervention treatment for 1 time, post-admission treatment, self-complaint of liver pain, score 6, examination show: the liver shed nodules, considering recurrences. When the external application treatment of the prescription 2 of the invention is given in a ward, the subjective pain is gradually relieved, the pain is not obvious after 8 days, and after 14 days, the pain is scored for 2 points, no adverse reaction occurs, and the effect is satisfactory.
Case four: left lung cancer with pleural effusion
Diagnosis of left lung cancer, left pleural effusion and 4 cycles of chemotherapy in hospital tumor of medical department in 2011 10 months of age 74 years of male Liza, evaluation of SD; extracting pleural effusion and perfusing chemotherapy, and rechecking CT: the mass is slightly bigger than the anterior one and a large amount of pleural effusion. The pain is scored for 7 points, the patient needs to be treated by morphine when suffering from the pain and is placed in the hospital, the patient is treated by the prescription in the invention example 2, the pain is relieved after 7 days, the pain is scored for 4 points, no adverse reaction occurs, the interval time of the morphine is prolonged compared with the previous interval time, and the curative effect is satisfactory.
Case five: esophageal cancer
In the case of Zhenzhi, male, 55 years old, and 2011, the patient is diagnosed as esophageal cancer in Beijing coordination hospital in 8 months and is treated with radiation after the treatment, the pain after the sternum is still obvious after 2 months, and the pain scores 5 points after the patient is hospitalized for further combination of Chinese and western medicine, the patient is treated with the formula 2 of the invention, and the pain is relieved earlier and scores 2 points after 7 days of treatment, so that the pain-relieving medicine treatment is not needed, no adverse reaction exists, and the curative effect is satisfactory.
Detailed Description
Example 1:
prescription: 30g of dragon's blood, 5g of toad venom, 75g of raw arisaema tuber, 75g of common monkshood mother root, 30g of natural indigo, 30g of borneol, 60g of frankincense and 60g of myrrh.
The use method comprises the following steps: grinding the raw materials into fine powder, and sieving with a 200-mesh sieve to obtain fine powder. Cleaning pain part before application, concocting the medicinal powder with boiling water into paste, spreading on a plaster cotton pad with thickness of about 0.3cm and area diameter of about 2cm larger than that of pain part skin, sequentially covering a layer of gauze and a layer of plastic film on the ointment, and sealing and fixing with desensitizing adhesive tape. The medicine is applied for 1 time every day for 8-12 hours.
Example 2:
prescription: 30g of dragon's blood, 5g of toad venom, 75g of raw arisaema consanguineum, 75g of monkshood, 30g of natural indigo, 30g of borneol, 60g of frankincense, 60g of myrrh, 3g of Chinese azalea flower, 30g of caulis Erycibes and 50g of cassia twig.
The use method comprises the following steps: grinding the raw materials into fine powder, and sieving with a 200-mesh sieve to obtain fine powder. Cleaning pain part before application, concocting the medicinal powder with boiling water into paste, spreading on a plaster cotton pad with thickness of about 0.3cm and area diameter of about 2cm larger than that of pain part skin, sequentially covering a layer of gauze and a layer of plastic film on the ointment, and sealing and fixing with desensitizing adhesive tape. The medicine is applied for 1 time every day for 8-12 hours.
Example 3:
the invention relates to the composition and the proportion of common raw material medicines (g)
| Square number | Dragon's blood | Toad venom | Rhizoma arisaematis | Radix Aconiti | Indigo naturalis | Borneol (borneol) | Olibanum (Boswellia carterii) | Myrrha | Chinese azalea flower | Caulis Erycibes | Ramulus Cinnamomi |
| 1 | 25 | 4 | 60 | 60 | 25 | 25 | 50 | 50 | 0 | 0 | 0 |
| 2 | 35 | 6 | 90 | 90 | 35 | 35 | 70 | 70 | 0 | 0 | 0 |
| 3 | 30 | 5 | 75 | 75 | 30 | 30 | 60 | 60 | 0 | 0 | 0 |
| 4 | 25 | 4 | 60 | 60 | 25 | 25 | 70 | 70 | 0 | 0 | 0 |
| 5 | 35 | 6 | 90 | 90 | 35 | 35 | 50 | 50 | 0 | 0 | 0 |
| 6 | 30 | 5 | 75 | 60 | 25 | 25 | 70 | 70 | 0 | 0 | 0 |
| 7 | 25 | 4 | 60 | 60 | 25 | 25 | 50 | 50 | 2.5 | 25 | 40 |
| 8 | 35 | 6 | 90 | 90 | 35 | 35 | 70 | 70 | 3.5 | 35 | 60 |
| 9 | 30 | 5 | 75 | 75 | 30 | 30 | 60 | 60 | 3 | 30 | 50 |
| 10 | 25 | 4 | 60 | 60 | 25 | 25 | 70 | 70 | 3.5 | 35 | 60 |
| 11 | 35 | 6 | 90 | 90 | 35 | 35 | 50 | 50 | 2.5 | 25 | 40 |
| 12 | 30 | 5 | 75 | 60 | 25 | 25 | 70 | 70 | 3.5 | 30 | 50 |
The raw materials are pulverized into fine powder, and can be prepared into external preparations such as external application agent, rubber paste, ointment, cataplasm and the like according to clinical needs, so that the claimed effect of the invention can be achieved.
Claims (7)
1. A traditional Chinese medicine composition for external use for treating cancer pain is characterized in that the effective components of the traditional Chinese medicine composition are prepared from the following raw material medicines in parts by weight: 25-35 parts of dragon's blood, 4-6 parts of toad venom, 60-90 parts of raw arisaema tuber, 60-90 parts of common monkshood mother root, 25-35 parts of natural indigo, 25-35 parts of borneol, 50-70 parts of frankincense and 50-70 parts of myrrh.
2. The external traditional Chinese medicine composition according to claim 1, which is characterized in that the composition of each raw material medicine is as follows: 30 parts of dragon's blood, 5 parts of toad venom, 75 parts of raw arisaema tuber, 75 parts of common monkshood mother root, 30 parts of natural indigo, 30 parts of borneol, 60 parts of frankincense and 60 parts of myrrh.
3. A traditional Chinese medicine composition for external use for treating cancer pain is characterized in that the effective components of the traditional Chinese medicine composition are prepared from the following raw material medicines in parts by weight: 25-35 parts of dragon's blood, 4-6 parts of toad venom, 60-90 parts of raw arisaema tuber, 60-90 parts of common monkshood mother root, 25-35 parts of natural indigo, 25-35 parts of borneol, 50-70 parts of frankincense, 50-70 parts of myrrh, 2.5-3.5 parts of Chinese azalea flower, 25-35 parts of erycibe obtusifolia and 40-60 parts of cassia twig.
4. The external traditional Chinese medicine composition according to claim 3, which is characterized in that the composition of each raw material medicine is as follows: 30 parts of dragon's blood, 5 parts of toad venom, 75 parts of raw arisaema tuber, 75 parts of common monkshood mother root, 30 parts of natural indigo, 30 parts of borneol, 60 parts of frankincense, 60 parts of myrrh, 3 parts of Chinese azalea flower, 30 parts of erycibe obtusifolia and 50 parts of cassia twig.
5. The topical Chinese medicinal composition according to claim 1 or 2, characterized in that the composition is prepared by the following method: grinding all the raw materials into fine powder, sieving with 200 mesh sieve, adding appropriate adjuvant, and making into topical unguent or patch.
6. The topical Chinese medicinal composition according to claim 3 or 4, characterized in that the composition is prepared by the following method: grinding all the raw materials into fine powder, sieving with 200 mesh sieve, adding appropriate adjuvant, and making into topical unguent or patch.
7. Use of the topical Chinese medicinal composition of any one of claims 1 to 4 in the manufacture of a medicament for the treatment of cancer pain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510675585.1A CN105168723B (en) | 2015-10-19 | 2015-10-19 | A topical Chinese medicinal composition for treating cancer pain, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510675585.1A CN105168723B (en) | 2015-10-19 | 2015-10-19 | A topical Chinese medicinal composition for treating cancer pain, and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105168723A CN105168723A (en) | 2015-12-23 |
| CN105168723B true CN105168723B (en) | 2020-01-17 |
Family
ID=54891474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510675585.1A Active CN105168723B (en) | 2015-10-19 | 2015-10-19 | A topical Chinese medicinal composition for treating cancer pain, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105168723B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106389742A (en) * | 2016-10-09 | 2017-02-15 | 上海民生志远健康管理科技发展有限公司 | Traditional Chinese medicine composition for curing cancer pain |
| CN108567964A (en) * | 2018-07-06 | 2018-09-25 | 昆明市中医医院 | Tumour eliminating and analgesic cream |
| CN113476407A (en) * | 2021-08-06 | 2021-10-08 | 孙栋梁 | Gangrene clearing and applying powder and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1110598A (en) * | 1995-01-13 | 1995-10-25 | 李勤 | Hot application for stopping cancer pain |
-
2015
- 2015-10-19 CN CN201510675585.1A patent/CN105168723B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1110598A (en) * | 1995-01-13 | 1995-10-25 | 李勤 | Hot application for stopping cancer pain |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105168723A (en) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104523865B (en) | Medicine for treating breast diseases | |
| CN105168723B (en) | A topical Chinese medicinal composition for treating cancer pain, and its preparation method | |
| CN100411668C (en) | A cancer-treating medicine | |
| CN102920976B (en) | External traditional Chinese medicine composition for preventing and treating liver cancer pain | |
| CN100531791C (en) | Antineoplastic, anti-cancer drugs | |
| CN104000863A (en) | Medicinal composition for treating malignant tumor accompanied with gall-stone and preparation method and medical application thereof | |
| CN104435544A (en) | Traditional Chinese medicine oral liquid for treating leukemia through being cooperated with chemotherapy and preparation method thereof | |
| CN104888149B (en) | The drug and its preparation process for treating cervical carcinoma | |
| CN102671046A (en) | Chinese medicament for treating chronic appendicitis | |
| CN101961455A (en) | Traditional Chinese medicine for treating chronic colitis disease | |
| CN104666671A (en) | Anti-cancer analgesic medicine of Chinese yew and preparation method of anti-cancer analgesic medicine | |
| CN110624079A (en) | A Chinese medicinal composition for improving cancer-induced fatigue and tumor radiotherapy and chemotherapy reaction | |
| CN103191306B (en) | Chinese medicinal external application medicament for treating thyroid nodules | |
| CN101584802B (en) | Chinese medicinal capsule for treating malignant lymphoma | |
| CN101524465B (en) | External dipping medicine for remedying cancer | |
| CN101244181A (en) | Plaster for bone paralysis with function of qufengshengshi, blood circulation activating and stasis removing, and removing the obstruction in the channels to relieve pain, and preparation thereof | |
| CN109876063A (en) | The Chinese medicine composition for treating lump | |
| CN104623534A (en) | Anodyne for advanced liver cancer | |
| CN103751615B (en) | A kind of external application of Chinese medicine agent for the treatment of acute radiation-induced esophagitis | |
| CN107510804A (en) | Treat the Chinese medicine of manic disorder | |
| CN107510805A (en) | Treat the Chinese medicine of depression | |
| CN104688913B (en) | Treat the Chinese medicine composition of herpes zoster sequelae | |
| CN101862395A (en) | Tumor curing medicine containing saussurea involucrate and preparation method thereof | |
| CN104306811B (en) | A kind of Chinese medicine composition for treating children's psoriasis vulgaris | |
| CN103656319A (en) | Application for treating acute radiation-induced esophagitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |